Alternative und integrative Medizin

Background: Acute Promyelocytic Leukemia (APL) is a well-defined subtype of Acute Myelocytic Leukemia (AML) and known by t (15;17) (PML-RARA) mutation. 20%-40% of AML patients indicate FMS-Like Tyrosine kinase 3 (FLT3) mutations. FLT3 mutations contain two famous mutations: FLT3-ITD (Internal Tandem Duplication) and FLT3-TKD (Tyrosine Kinase II Domain).

Objectives: Many studies have been done on FLT3-ITD. These studies have been acknowledged that the FLT3-ITD mutation had poor prognosis of on AML patients. This study was performed on two APL and APL+FLT3-ITD groups. This study aimed to compare differences in blood laboratory assays between APL and APL+FLT3-ITD patients.

Methods: This study contained 73 patients which divided in two groups: Acute promyelocytic leukemia and FLT3-ITD+acute promyelocytic leukemia. The study methods included: Cell counting and Peripheral Blood Smear (PBS), karyotype, extraction of mRNA and DNA, cDNA synthesis electrophoresis.

Results: This study was ruled out on patients involved with acute promyelocytic leukemia in GHAEM hospital Mashhad, Iran. All patients were diagnosed with t (15; 17) (PML-RARA). The age range of patients was 7-63 (mean: 30.86) and 58 (79.5%) (Male: 22, Female: 36) of patients were involved solely with APL and 15 (20.5%) (Male: 10, Female: 5) of them were APL+FLT3-ITD mutation. Blood parameters that were analyzed included: White Blood Cell (WBC), Red Blood Cell (RBC), Hemoglobin (Hb), Hematocrit (Hct), Mean Cell Volume (MCV) and Platelet (PLT) count. Each group of patients’ population was categorized into HIGH Risk factors and LOW Risk factors.

Conclusion: The consequence of current study demonstrated that FLT3-ITD mutation had a bad effect on laboratory assays in patients involved with Acute Promyelocytic Leukemia.